Miniatura

Fitxers

e006031.full.pdf (952.36 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2025-10-01

Llicència de publicació

cc-by-nc (c) Puche Larrubia, María Ángeles et al., 2025
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/223776

Seventeen-year reassessment of diagnostic transitions, biologic therapy initiation and mortality in spondyloarthritis: results from the REGISPON-3 study

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1136/rmdopen-2025-006031

Resum

Objectives To evaluate disease evolution, diagnostic transitions, time to biologic treatment initiation and mortality in patients with spondyloarthritis (SpA) after 17 years from the original Spanish Registry of Spondyloarthritis (REGISPONSER).Methods Spondyloarthritis Registry 3 (REGISPON-3) is a two-timepoint longitudinal study with patients fulfilling the European Spondyloarthropathy Study Group criteria participating in the REGISPONSER study and re-evaluated after 17 years. Clinical, laboratory, radiological and treatment data were collected and compared with baseline. Diagnostic changes according to the rheumatologist's judgement and their associated factors were analysed using multivariable logistic regression. Time to initiation of biologic therapy was evaluated using Kaplan-Meier survival analysis.Results A total of 536 patients from the REGISPONSER study conducted in 2004 were contacted in 2021 for the REGISPON-3 visit. Of these, 411 were physically re-evaluated, while 125 were confirmed deceased. Among the 411 patients, 31.6% experienced a change in diagnosis in the REGISPON-3 visit, mainly from undifferentiated SpA to axial SpA or psoriatic arthritis. In multivariable analysis, dactylitis, younger age and lower Bath Ankylosing Spondylitis Radiology Index scores were associated with diagnostic change. The use of biologic disease-modifying antirheumatic drugs (bDMARDs) increased from 13.1% to 52.1%. However, the median time to first bDMARD from symptom onset was 32 years (95% CI 30 to 35) and 28 years from diagnosis (95% CI 26 to 32). Among the 125 patients who died, the leading causes were infections (21.6%), cardiovascular (CV) events (20.0%) and cancer (19.2%).Conclusions This long-term reassessment reveals significant diagnostic changes in SpA and a mortality burden mainly attributed to infections and CV diseases.

Matèries

Reumatisme, Artrosi, Inflamació

Matèries (anglès)

Rheumatism, Osteoarthritis, Inflammation

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

PUCHE LARRUBIA, María ángeles, LADEHESA PINEDA, Lourdes, ÁBALOS AGUILERA, María carmen, RUIZ VILCHEZ, Desirée, BERBEL ARCOBÉ, Laura, JUANOLA, Xavier, ARÉVALO SALAET, Marta, MORENO, Mireia, ALMODÓVAR, Raquel, PIJOAN MORATALLA, Cristina, JOVEN, Beatriz, VALERO EXPÓSITO, Marta, GARCÍA GARCÍA, Verónica, MORENO-RAMOS, Manuel j., ORNILLA, Enrique, MARÍA GRANADOS, Raquel ena, MARGARETA MOLDOVAN, Diana maria, COLLANTES SÁNCHEZ, Carlos m., ESCUDERO CONTRERAS, Alejandro, COLLANTES ESTÉVEZ, Eduardo, LÓPEZ MEDINA, Clementina. Seventeen-year reassessment of diagnostic transitions, biologic therapy initiation and mortality in spondyloarthritis: results from the REGISPON-3 study. _RMD Open_. 2025. Vol. 11, núm. 4, pàgs. e006031. [consulta: 24 de gener de 2026]. ISSN: 2056‑5933. [Disponible a: https://hdl.handle.net/2445/223776]

Exportar metadades

JSON - METS

Compartir registre